[Use of vancomycin in the treatment of severe Staphylococcus aureus infection. Description of 3 cases]

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Rising prevalence of antibiotic-multiresistant Staphylococcus strains (e.g., Staphylococcus aureus, Staphylococcus epidermidis) in hospital settings.
• Significant challenges in treating severe septic forms and managing systemic bacterial spread due to resistance.
• Need for effective therapeutic options against resistant Gram-positive bacterial infections.

Observation:

• Evaluation of intravenous vancomycin treatment outcomes in three patients.
• Patients presented with sepsis and secondary localizations including endocarditis, osteomyelitis, and pneumonia.
• All infections were caused by Gram-positive Staphylococcus aureus strains.

Findings:

• Intravenous vancomycin demonstrated efficacy in treating all three cases of severe Staphylococcus aureus sepsis.
• The treatment was well-tolerated, with no significant adverse side effects observed in the patients.
• Vancomycin proved effective against Gram-positive Staphylococcus aureus, even in complicated systemic infections.

Implications:

• Intravenous vancomycin represents a viable treatment option for severe Staphylococcus aureus infections, including those with secondary complications.
• The findings support the continued use of vancomycin in managing hospital-acquired infections caused by resistant Gram-positive bacteria.
• Further research into vancomycin's role in combating multidrug-resistant Staphylococcus strains is warranted.